STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title	1
		or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	1
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	3
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods	5
		of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case	5
		ascertainment and control selection. Give the rationale for the choice	
		of cases and controls	
		(b) For matched studies, give matching criteria and the number of	
		controls per case	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential	6
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	6
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	6
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	6
		for confounding	
		(b) Describe any methods used to examine subgroups and	6
		interactions	
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how matching of cases and controls was	-
		addressed	
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	7
		numbers potentially eligible, examined for eligibility, confirmed	
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	7
		clinical, social) and information on exposures and potential	
		confounders	

		(b) Indicate number of participants with missing data for each	
		variable of interest	
Outcome data	15*	Report numbers in each exposure category, or summary measures of	7
		exposure	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	d 7
		estimates and their precision (eg, 95% confidence interval). Make	
		clear which confounders were adjusted for and why they were	
		included	
		(b) Report category boundaries when continuous variables were	7
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of	13
		potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	12
		objectives, limitations, multiplicity of analyses, results from	
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the	14
		present study and, if applicable, for the original study on which	
		the present article is based	

^{*}Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.